WallStreetZenWallStreetZen

NASDAQ: MBOT
Microbot Medical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MBOT

Based on 1 analyst offering 12 month price targets for Microbot Medical Inc

Min Forecast
$12.00+438.12%
Avg Forecast
$12.00+438.12%
Max Forecast
$12.00+438.12%

Should I buy or sell MBOT stock?

Based on 1 analyst offering ratings for Microbot Medical Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MBOT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates MBOT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their MBOT stock forecasts and price targets.

MBOT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-15

1 of 1

Forecast return on equity

Is MBOT forecast to generate an efficient return?

Company
15.3%
Industry
16.9%
Market
261.18%
MBOT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MBOT forecast to generate an efficient return on assets?

Company
14.02%
Industry
12.93%
MBOT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MBOT earnings per share forecast

What is MBOT's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.24
Avg 2 year Forecast
$0.10

MBOT revenue forecast

What is MBOT's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$5.7M
Avg 2 year Forecast
$69.4M

MBOT vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
MBOT$2.23$12.00+438.12%Buy
ZTEK$0.83N/AN/A
PDEX$36.24$56.00+54.53%Buy
NEPH$5.70$6.00+5.26%Strong Buy
AVR$4.49N/AN/A
View Top Medical Stocks

Microbot Medical Stock Forecast FAQ

Is Microbot Medical Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MBOT) stock is to Buy MBOT stock.

Out of 1 analyst, 0 (0%) are recommending MBOT as a Strong Buy, 1 (100%) are recommending MBOT as a Buy, 0 (0%) are recommending MBOT as a Hold, 0 (0%) are recommending MBOT as a Sell, and 0 (0%) are recommending MBOT as a Strong Sell.

If you're new to stock investing, here's how to buy Microbot Medical stock.

What is MBOT's earnings growth forecast for 2025-2026?

(NASDAQ: MBOT) Microbot Medical's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 50.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,855.71%.

Microbot Medical's earnings in 2025 is -$12,708,000.On average, 3 Wall Street analysts forecast MBOT's earnings for 2025 to be -$11,149,646, with the lowest MBOT earnings forecast at -$10,712,405, and the highest MBOT earnings forecast at -$11,477,577.

In 2026, MBOT is forecast to generate $4,645,686 in earnings, with the lowest earnings forecast at $4,463,502 and the highest earnings forecast at $4,782,324.

What is MBOT's revenue growth forecast for 2025-2026?

(NASDAQ: MBOT) Microbot Medical's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 5.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,364.9%.

Microbot Medical's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast MBOT's revenue for 2025 to be $261,570,328, with the lowest MBOT revenue forecast at $251,276,945, and the highest MBOT revenue forecast at $269,267,591.

In 2026, MBOT is forecast to generate $3,159,066,329 in revenue, with the lowest revenue forecast at $3,035,181,375 and the highest revenue forecast at $3,251,980,045.

What is MBOT's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: MBOT) forecast ROA is 14.02%, which is higher than the forecast US Medical Instruments & Supplies industry average of 12.93%.

What is MBOT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MBOT price target, the average MBOT price target is $12.00, with the highest MBOT stock price forecast at $12.00 and the lowest MBOT stock price forecast at $12.00.

The Wall Street analyst predicted that Microbot Medical's share price could reach $12.00 by Oct 15, 2026. The average Microbot Medical stock price prediction forecasts a potential upside of 438.12% from the current MBOT share price of $2.23.

What is MBOT's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: MBOT) Microbot Medical's current Earnings Per Share (EPS) is -$0.58. On average, analysts forecast that MBOT's EPS will be -$0.24 for 2025, with the lowest EPS forecast at -$0.24, and the highest EPS forecast at -$0.25. In 2026, MBOT's EPS is forecast to hit $0.10 (min: $0.10, max: $0.11).

What is MBOT's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: MBOT) forecast ROE is 15.3%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.